Devinderpal Randhawa - SUNY University at Buffalo

1 Active

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
Randhawa, D. (PI)
Fortrea Incorporated
03/2/26 → 09/1/30
Project: Research